



App '13

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:428911 CAPLUS
 DN 137:6205
 TI Preparation of benzazepinones, isoquinolinones and related compounds as inhibitors of poly(ADP-ribose) polymerase (PARP) for the prevention and/or treatment of tissue damage from cell trauma or cell death due to necrosis or apoptosis.
 IN Ferraris, Dana V.; Li, Jia-He; Kalish, Vincent J.; Zhang, Jie
 PA Guilford Pharmaceuticals Inc., USA
 SO PCT Int. Appl., 152 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044183	A2	20020606	WO 2001-US44815	20011130
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002036521	A5	20020611	AU 2002-36521	20011130
	US 2003022883	A1	20030130	US 2001-996776	20011130
PRAI	US 2000-250132P	P	20001201		
	US 2001-310274P	P	20010809		
	WO 2001-US44815	W	20011130		
OS	MARPAT 137:6205				
GI					




I



II



III



IV

AB This invention discloses the prepn. of title compds. I and II, their pharmaceutically acceptable salts, and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP) [wherein: A = N, C, CH₂, CH; B = C, N, NH, S, SO, SO₂; X = C, CH, N; Y = C, N; Z = C, CH₂, N, CO; provided that at least one of X, Y, or Z is N; R1, R2, R3, R5 when present are optionally or independently = H, OH, :O, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, amine, COR₈ (R₈ = H, OH, (un)substituted alkyl,

alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl), OR6, NR6R7 (R6, R7 independently = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl); R1, R2, R3, R5 optionally form ring through a straight or branched C1-4alkyl which may addnl. contain 1-2 double or triple bonds; R4 = 1-3 of H, halo, or alkyl; with proviso that when A, X, or Z = C, then R1, R2, R3 when present may also independently = halogen, CN, O; R9, R10, R11, R12 optionally or independently = H, halogen, amino, OH, halo-amine, O-alkyl, O-aryl, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, COR8; R13 = 1-3 of H, halogen, alkoxy, alkyl]. For example, cyclocondensation of formylindazole III (prepd. from Me indole-4-carboxylate and NaNO2/AcOH), with hydrazine provided claimed benzoazulenone IV as a white solid. Benzoazulenone IV inhibited human recombinant PARP at an IC50 of 0.018 .mu.M. PARP IC50 inhibition studies for an addnl. 156 examples are provided, ranging in values from 0.01 to 20 .mu.M. Biol. data are provided for the in vivo treatment of focal cerebral ischemia and gout via PARP inhibition with selected compds. II. The present invention is believed to protect cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide through inhibition of PARP activity.


IT 433726-67-1P 433726-71-7P 433726-76-2P
 433726-79-5P 433726-80-8P 433726-81-9P
 433726-86-4P 433727-89-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; prepn. of benzazepinones, isoquinolinones and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP))


RN 433726-67-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-methoxy- (9CI) (CA INDEX NAME)




RN 433726-71-7 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 433726-76-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 433726-79-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 433726-80-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 433726-81-9 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-amino- (9CI) (CA INDEX NAME)



433726-68-2P 433726-69-3P 433726-70-6P
 433726-72-8P 433726-73-9P 433726-74-0P
 433726-75-1P 433726-77-3P 433726-78-4P
 433726-82-0P 433726-83-1P 433726-84-2P
 433726-85-3P 433726-87-5P 433726-88-6P
 433726-89-7P 433726-90-0P 433727-88-9P
 433727-90-3P 433727-91-4P 433727-92-5P
 433727-93-6P 433727-94-7P 433727-95-8P
 433727-96-9P 433727-97-0P 433727-98-1P
 433727-99-2P 433728-00-8P 433728-01-9P
 433728-02-0P 433728-03-1P 433728-04-2P
 433728-05-3P 433728-06-4P 433728-07-5P
 433728-08-6P 433728-09-7P 433728-10-0P
 433728-11-1P 433728-12-2P 433728-13-3P
 433728-14-4P 433728-15-5P 433728-16-6P
 433728-17-7P 433728-18-8P 433728-19-9P
 433728-20-2P 433728-21-3P 433728-22-4P
 433728-23-5P 433728-24-6P 433728-25-7P
 433728-26-8P 433728-27-9P 433728-28-0P
 433728-29-1P 433728-31-5P 433728-32-6P
 433728-33-7P 433728-34-8P 433728-35-9P
 433728-36-0P 433728-37-1P 433728-38-2P
 433728-39-3P 433728-40-6P 433728-41-7P
 433728-42-8P 433728-43-9P 433728-44-0P
 433728-45-1P 433728-46-2P 433728-47-3P
 433728-48-4P 433728-50-8P 433728-51-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; prepn. of benzazepinones, isoquinolinones and
 related

compds. as inhibitors of poly(ADP-ribose) polymerase (PARP))


RN 94191-07-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)




RN 433726-68-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 8-methoxy- (9CI) (CA INDEX NAME)




RN 433726-69-3 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-chloro- (9CI) (CA INDEX NAME)




RN 433726-70-6 CAPLUS

CN Benzo[c]-1,5-naphthyridine-2,6-dione, 1,5-dihydro- (9CI) (CA INDEX NAME)




RN 433726-72-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-chloro- (9CI) (CA INDEX NAME)




RN 433726-73-9 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino- (9CI) (CA INDEX NAME)




RN 433726-74-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433726-75-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[[3-(diethylamino)propyl]amino]-
(9CI) (CA INDEX NAME)




RN 433726-77-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 433726-78-4 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(2,5-diazabicyclo[2.2.1]hept-2-yl)-
(9CI) (CA INDEX NAME)




RN 433726-82-0 CAPLUS

CN Acetamide, 2-chloro-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-
 (9CI) (CA INDEX NAME)




RN 433726-83-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-4-oxido-1-piperazinyl)-
,
1-oxide (9CI) (CA INDEX NAME)




RN 433726-84-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-
(9CI) (CA INDEX NAME)




RN 433726-85-3 CAPLUS

CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 433726-87-5 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-[(tetrahydro-2-furanyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 433726-88-6 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(1-methylethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 433726-89-7 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-cyclopentyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RN 433726-90-0 CAPLUS


CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-
(9CI) (CA INDEX NAME)



RN 433727-88-9 CAPLUS

CN Benzo[c]-1,5-naphthyridine-2,6-dione, 1,5-dihydro-, monohydrobromide
(9CI)


(CA INDEX NAME)



● HBr


RN 433727-90-3 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-4-oxido-1-piperazinyl)-
(9CI) (CA INDEX NAME)




RN 433727-91-4 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-1,4-dioxido-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 433727-92-5 CAPLUS


CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(cyclopropylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 433727-93-6 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433727-94-7 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-(cyclopropylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433727-95-8 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-acetonitrile, 5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433727-96-9 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-acetic acid, 5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, ethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433727-97-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2,5-dimethylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA

INDEX

NAME)


Absolute stereochemistry.



RN 433727-98-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(4-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433727-99-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(4-methoxyphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 433728-00-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3,4-dimethylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA

INDEX
NAME)

Absolute stereochemistry.




RN 433728-01-9 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3,4-dichlorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA

INDEX
NAME)


Absolute stereochemistry.



RN 433728-02-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-03-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3-methylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-04-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3-chlorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-05-3 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2-methylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-06-4 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2-chlorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-07-5 CAPLUS

CN Benzoic acid, 4-[[(1S,4S)-5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-08-6 CAPLUS

CN Benzoic acid, 3-[[(1S,4S)-5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-09-7 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[[(1S,4S)-5-[(4-methylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-10-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[[4-(phenylmethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 433728-11-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[[3-(benzyloxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-12-2 CAPLUS


CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[[4-(2-pyridinylmethyl)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI)

piperazinyl]- (9CI) (CA INDEX NAME)




RN 433728-13-3 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 433728-14-4 CAPLUS


CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-(dimethylamino)-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 433728-15-5 CAPLUS

CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-
 , monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 433728-16-6 CAPLUS

CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-
 4-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 433728-17-7 CAPLUS
CN 1(2H)-Pyridineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-
2-yl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 433728-18-8 CAPLUS
CN 2H-Isoindole-2-acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-
2-yl)- (9CI) (CA INDEX NAME)




RN 433728-19-9 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-(dipentylamino)- (9CI) (CA INDEX NAME)




RN 433728-20-2 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-21-3 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-[(2-phenylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-22-4 CAPLUS

CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 433728-23-5 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-(dipropylamino)- (9CI) (CA INDEX NAME)




RN 433728-24-6 CAPLUS

CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 433728-25-7 CAPLUS

CN Acetamide, 2-(dibutylamino)-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 433728-26-8 CAPLUS


CN 4-Morpholineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 433728-27-9 CAPLUS
 CN 1H-Imidazole-1-acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 433728-28-0 CAPLUS
 CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-(dimethylamino)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 433728-29-1 CAPLUS
 CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-, hydrochloride (9CI) (CA INDEX NAME)




x HCl

RN 433728-31-5 CAPLUS
 CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-
 4-(1-pyrrolidinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 433728-30-4
 CMF C23 H27 N5 O2




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 433728-32-6 CAPLUS
 CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-
 4-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 433728-33-7 CAPLUS
 CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-34-8 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[3-(1-methyl-2-pyrrolidinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-35-9 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 433728-36-0 CAPLUS


CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 433728-37-1 CAPLUS


CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-

4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 433728-38-2 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-39-3 CAPLUS

CN Acetamide, 2-[[2-(diethylamino)ethyl]amino]-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 433728-40-6 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-41-7 CAPLUS

CN Acetamide, 2-[[3-(diethylamino)propyl]amino]-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 433728-42-8 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[3-(dimethylamino)propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 433728-43-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)hexahydro- (9CI) (CA INDEX NAME)




RN 433728-44-0 CAPLUS

CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 433728-45-1 CAPLUS

CN 1-Piperazineacetamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 433728-46-2 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(2-oxo-1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 433728-47-3 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-48-4 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-1-piperazinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 433726-76-2


CMF C17 H18 N4 O



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 433728-50-8 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 433728-51-9 CAPLUS

CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




IT **433728-81-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT (Reactant or reagent)


(prepn. of benzazepinones, isoquinolinones and related compds. as
 inhibitors of poly(ADP-ribose) polymerase (PARP))

RN 433728-81-5 CAPLUS

CN Acetamide, 2-chloro-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:162346 CAPLUS
 DN 134:359384
 TI Photoreaction of 2-Halo-N-pyridinylbenzamide: Intramolecular Cyclization Mechanism of Phenyl Radical Assisted with n-Complexation of Chlorine Radical
 AU Park, Yong-Tae; Jung, Chang-Hee; Kim, Moon-Sub; Kim, Kwang-Wook; Song, Nam Woong; Kim, Dongho
 CS Department of Chemistry, Kyungpook National University, Taegu, 702-701, S. Korea
 SO Journal of Organic Chemistry (2001), 66(7), 2197-2206
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 GI




AB The photochem. of 2-halo-N-pyridinylbenzamide I ($R = H, Cl, Br$; $R_1 = H, Me$; $R_2 = 4\text{-N-(4-pyridinyl)}, 3\text{-N-(3-pyridinyl)}, 2\text{-N-(2-pyridinyl)}$) and chlorobenzanilide I ($R = Cl, R_1 = H, R_2 = CH$) was studied in aq. acetonitrile. The photoreaction of 2-chloro-N-pyridinylbenzamides produced photocyclized products, benzo[c]naphthyridinones in high yield, whereas the bromo analogs produced extensively photoreduced products, N-pyridinylbenzamides with minor photocyclized product. Since the photocyclization reaction of 2-chloro-N-pyridinylbenzamide was retarded by the presence of oxygen and sensitized by the presence of a triplet sensitizer, acetone or acetophenone, a triplet state of the chloro analog was involved in the reaction. Since several radical intermediates, particularly n-complexes of chlorine radical, were identified in the laser flash photolysis of 2-chloro-N-pyridinylbenzamide, an intramol. cyclization mechanism of Ph radical assisted with n-complexation of chlorine radical for the cyclization reaction was proposed: the triplet state (78 kcal/mol) of the chloro analog, which was populated by the excitation underwent a homolytic cleavage of the C-Cl bond to give Ph and chlorine radicals; while chlorine radical held the neighbor pyridinyl ring with its n-complexation, the intramol. arylation of the Ph radical with the pyridinyl ring proceeded to produce a conjugated 2,3-dihydropyridinyl radical and then the conjugated radical aromatized to afford a cyclized product, benzo[c]naphthyridinone by ejecting a hydrogen. The photoredn. product can be formed by hydrogen atom abstraction of the Ph .sigma. radical from the environment.

IT **94191-07-8P**, Benzo[c][1,5]naphthydrin-6(5H)-one
 RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
 (cyclized photoproduct; photolysis of halopyridinylbenzamide derivs.)
 RN 94191-07-8 CAPLUS
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:879316 CAPLUS
 DN 134:193358
 TI Alkylbenzonaphthyridinones and benzonaphthyridinium quaternary salts
 AU Dondela, B.; Sliwa, W.
 CS Institute of Chemistry, Pedagogical University, Czestochowa, 42-201,
 Pol.
 SO Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya
 Geterotsiklicheskikh Soedinenii) (2001), Volume Date 2000, 36(7), 830-
 836
 CODEN: CHCCAL; ISSN: 0009-3122
 PB Consultants Bureau
 DT Journal
 LA English
 AB Methyl- and ethylbenzonaphthyridinones, along with
 ethylbenzonaphthyridinium iodides, 2,5-dimethyl-1,5-
 benzo[c]naphthyridinium iodide, and isomeric N-(3-
 bromopropyl)benzonaphthyridinium bromides were synthesized and their
 structures were confirmed by 1H NMR. Two of the obtained compds.
 exhibited antibacterial activity.
 IT **327096-09-3P**
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation) (prepn. and antibacterial
 activity)
 RN 327096-09-3 CAPLUS
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 5-methyl- (9CI) (CA INDEX NAME)




IT **327096-11-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of benzonaphthyridinones and benzonaphthyridinium salts)
 RN 327096-11-7 CAPLUS
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 5-ethyl- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1985:45857 CAPLUS
 DN 102:45857
 TI Palladium-catalyzed cyclization of 2-substituted halogenoarenes by dehydrohalogenation
 AU Ames, D. E.; Opalko, A.
 CS Chem. Dep., Chelsea Coll., London, SW3 6LX, UK
 SO Tetrahedron (1984), 40(10), 1919-25
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English
 OS CASREACT 102:45857
 GI




AB Cyclodehydrohalogenation mediated by Pd catalysts and solvents with different bases (the most satisfactory system being Pd(OAc)₂ in AcNMe₂ with Na₂CO₃ as base) has been examd. as a route to some heterocyclic systems. Whereas dehydrogenative cyclization processes require stoichiometric amts. of Pd(II) reagent, the present procedure involves only catalytic amts. (0.1M proportion, or less), of Pd compd. The prepn. of dibenzofuran, carbazole, fluorenone, phenanthridone, 6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide (I), 6H-dibenzo[b,d]pyran and benzofuran[2,3-b]pyridine derivs. is described. The cyclization of 3-benzamido-2-chloropyridine (II) to 6-hydroxybenzo[c][1,5]naphthyridine (III) illustrates the regiospecificity of the process.

IT 94191-07-8P

RL: FORM (Formation, nonpreparative); PREP (Preparation)
 (formation of, by palladium-catalyzed cyclization of
 benzamidochloropyridine)


RN 94191-07-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1976:180196 CAPLUS
 DN 84:180196
 TI 4-Substituted amino-2,6-dioxo-pyrido[3,2-c]isoquinoline derivatives
 IN Kobayashi, Goro
 PA Kohjin Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51011797	A2	19760130	JP 1974-81726	19740718
	JP 57040832	B4	19820830		
PRAI	JP 1974-81726		19740718		
GI					



I



II


AB The pyridoisoquinoline was prep'd. by reaction of the methylthio deriv. II with H₂NCH₂CH(OEt)₂. I had sedative and anticonvulsant activities (no data). Thus, fusion of 2 mmoles II with 5 mmoles H₂NCH₂CH(OEt)₂ at 150.degree. for 1 hr gave 85% I.

IT **54706-14-8P**

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 54706-14-8 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 4-[(2,2-diethoxyethyl)amino]-1,2,5,6-tetrahydro-2,6-dioxo- (9CI) (CA INDEX NAME)




IT **54706-44-4**

RL: RCT (Reactant); RACT (Reactant or reagent)

RN 54706-44-4 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 1,2,5,6-tetrahydro-4-(methylthio)-2,6-dioxo- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 1975:72760 CAPLUS

DN 82:72760

TI Heterocyclic ketenethioacetal derivatives. IV. Reactions of 1,2,3,4-tetrahydro-1,3-dioxoisoquinoline and 1,2,3,4-tetrahydro-1,4-dioxoisoquinoline with ketenethioacetals and reaction of these products
AU Ueno, Seiichi; Tominaga, Yoshinori; Matsuda, Yoshiro; Kobayashi, Goro
CS Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, Japan
SO Chemical & Pharmaceutical Bulletin (1974), 22(11), 2624-34
CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB Reaction of 1,3-dioxo- or 1,4-dioxo-1,2,3,4-tetrahydroisoquinolines with ketene thioacetals, e.g., (MeS)2C:C(CN)CO2Me, gave the corresponding substitution products, e.g., I, in good yields. The application of these

reactions afforded pyrano[2,3-c]isoquinoline and pyrrolo[1,2-b]isoquinoline, III (Z = O), derivs. The reaction of I and related compds. with amines afforded recyclized products, 2-

benzopyranopyrano[3,4-

b]pyridine derivs., e.g. II. The reaction of III (Z = O) with amines gave

amino derivs., e.g., III (Z = NNH2). The reaction of IV with aminoacetal

afforded an aminoacetal deriv. which was treated with HCl to give a cyclized product V. The cyclization of derivs. of III (Z = O) with Et orthoformate or HCO2H gave pyrimidine derivs.

IT 54706-14-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(prepn. and cyclization of)

RN 54706-14-8 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 4-[(2,2-diethoxyethyl)amino]-1,2,5,6-tetrahydro-2,6-dioxo- (9CI) (CA INDEX NAME)



IT 54706-44-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(prepn. and reaction with sulfuric acid)

RN 54706-44-4 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 1,2,5,6-tetrahydro-4-(methylthio)-2,6-dioxo- (9CI) (CA INDEX NAME)




IT **54706-45-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 54706-45-5 CAPLUS


CN Benzo[c]-1,5-naphthyridine-3-carboxamide, 1,2,5,6-tetrahydro-4-(methylthio)-2,6-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 1 OF 2 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Reference(s):


1. Dondela, B.; Sliwa, W., Chem.Heterocycl.Comp. (Engl. Transl.), CODEN: CHCCAL, 36(7), <2000>, 830 - 836, Khim. Geterotsikl. Soedin., CODEN: KGSSAQ(7), <2000>, 944 - 950; BABS-6266153



L7 ANSWER 2 OF 2 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL


Reference(s):

1. Dondela, B.; Sliwa, W., Chem.Heterocycl.Comp. (Engl. Transl.), CODEN: CHCCAL, 36(7), <2000>, 830 - 836, Khim. Geterotsikl. Soedin., CODEN: KGSSAQ(7), <2000>, 944 - 950; BABS-6266153




L10 ANSWER 1 OF 2 MARPAT COPYRIGHT 2003 ACS
 AN 128:180325 MARPAT
 TI Preparation of dibenzofuranoxobutyrate and analogs as matrix metalloproteinase inhibitors
 IN Sliskovic, Drago Robert; Picard, Joseph Armand
 PA Warner-Lambert Company, USA; Sliskovic, Drago Robert; Picard, Joseph Armand
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806711	A1	19980219	WO 1997-US12389	19970716
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9737293	A1	19980306	AU 1997-37293	19970716
	EP 923569	A1	19990623	EP 1997-934175	19970716
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 2000516607	T2	20001212	JP 1998-509712	19970716
	ZA 9707328	A	19980219	ZA 1997-7328	19970814
	US 6020366	A	20000201	US 1998-171833	19981027
PRAI	US 1996-24025P		19960816		
	WO 1997-US12389		19970716		
GI					




AB Title compds. [I; R = CR₆R₇CH₂CH(NR₄R₅)COR₃; R₁, R₂ = H, halo, alkyl, alkoxy, etc.; R₃ = OH, alkoxy, aryloxy, NHOH, etc.; R₄, R₅ = H, alkyl, aryl, acyl, etc.; R₆ = H and R₇ = OH or SH; R₆R₇ = O, S, NOH, NNH₂, etc.;
 Y = O, SO₀₋₂, NR₁, CH₂, (NH)CO, etc.; W, W₁, Z, Z₁ = CR₁ or N] were prepd.
 Thus, dibenzofuran was acylated by N-trifluoroacetyl-L-aspartic acid anhydride to give (S)-R₈COCH₂CH(NHCOCF₃)CO₂H (R₈ = 2-dibenzofuranyl).
 Data for biol. activity of I were given.


MSTR 1A




G9 = 8



G14 = 72-6 73-10




G15 = 88 / N




DER: and pharmaceutically acceptable salts and solvates
 MPL: claim 1
 STE: and isomers and stereoisomers


MSTR 1B




G9 = 5



G14 = 72-6 73-10



G15 = 88 / N




DER: and pharmaceutically acceptable salts and solvates
 MPL: claim 1
 STE: and isomers and stereoisomers


RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 MARPAT COPYRIGHT 2003 ACS
 AN 120:107044 MARPAT
 TI Polycyclic heterocyclic agrochemical fungicides
 IN Daub, John Powell; Finkelstein, Bruce Lawrence; Kleier, Daniel Anthony
 PA du Pont de Nemours, E. I., and Co., USA
 SO PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314080	A1	19930722	WO 1992-US11329	19921230
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9334270	A1	19930803	AU 1993-34270	19921230
	EP 623125	A1	19941109	EP 1993-902842	19921230
	R: DE, DK, FR, GB				
	CN 1074443	A	19930721	CN 1993-100432	19930115
PRAI	US 1992-821724		19920115		
	WO 1992-US11329		19921230		
GI					




I



II

AB The title fungicidal compds. I [A = direct bond, (un)substituted bridging group; Q = fused (un)substituted benzene, (un)substituted naphthalene, (un)substituted thiophene, (un)substituted furan, (un)substituted pyrrole, (un)substituted pyridine, (un)substituted pyrimidine ring; R1-R4 = H, halogen, CN, HO, C1-6 alkyl, C1-4 haloalkyl, C1-4 alkylthio, C1-4 alkylsulfinyl, etc.; X = N, CR4; Y, Z = N, CR5; R5 = H, halogen, C1-2 alkyl, C1-2 alkoxy; the total no. of heteroatoms in ring A are .ltoreq.2] and their agriculturally suitable salts or metal complexes are prepd., and I-contg. formulations presented. Thus, pyrimidine II was prepd. (m.p. 166-166.5.degree.) and demonstrated antifungal activity against a variety of phytopathogenic fungi.

MSTR 1C



G10 = 41


$\text{C}_1\text{---G11}$

G12 = 70-7 71-2

$\text{C}_1\text{---G9}$
 $\text{C}_1\text{---G9}$

DER: or agriculturally suitable salts or metal complexes
MPL: claim 1
NTE: substitution is restricted
STE: including all geometric and stereoisomers

=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 11:56:51 ON 24 APR 2003)

FILE 'REGISTRY' ENTERED AT 11:57:01 ON 24 APR 2003

L1 STRUCTURE UPLOADED
L2 7 S L1
L3 94 S L1 FUL

FILE 'CAPLUS' ENTERED AT 11:57:28 ON 24 APR 2003

L4 6 S L3

FILE 'BEILSTEIN' ENTERED AT 11:58:01 ON 24 APR 2003

L5 0 S L1
L6 6 S L1 FUL
L7 2 S L6 NOT L3


FILE 'MARPAT' ENTERED AT 11:58:53 ON 24 APR 2003

L8 0 S L1
L9 3 S L1 FUL
L10 2 S L9 NOT L4


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	113.01	366.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.24	-5.15

STN INTERNATIONAL LOGOFF AT 11:59:32 ON 24 APR 2003


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1985:45857 CAPLUS
 DN 102:45857
 TI Palladium-catalyzed cyclization of 2-substituted halogenoarenes by dehydrohalogenation
 AU Ames, D. E.; Opalko, A.
 CS Chem. Dep., Chelsea Coll., London, SW3 6LX, UK
 SO Tetrahedron (1984), 40(10), 1919-25
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English
 OS CASREACT 102:45857
 GI



I



II



III

AB Cyclodehydrohalogenation mediated by Pd catalysts and solvents with different bases (the most satisfactory system being Pd(OAc)₂ in AcNMe₂ with Na₂CO₃ as base) has been examd. as a route to some heterocyclic systems. Whereas dehydrogenative cyclization processes require stoichiometric amts. of Pd(II) reagent, the present procedure involves only catalytic amts. (0.1M proportion, or less), of Pd compd. The prepn. of dibenzofuran, carbazole, fluorenone, phenanthridone, 6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide (I), 6H-dibenzo[b,d]pyran and benzofuran[2,3-b]pyridine derivs. is described. The cyclization of 3-benzamido-2-chloropyridine (II) to 6-hydroxybenzo[c][1,5]naphthyridine (III) illustrates the regiospecificity of the process.

IT 94191-07-8P

RL: FORM (Formation, nonpreparative); PREP (Preparation)
 (formation of, by palladium-catalyzed cyclization of
 benzamidochloropyridine)

RN 94191-07-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)

